Australia markets closed
  • ALL ORDS

    7,543.60
    +7.50 (+0.10%)
     
  • ASX 200

    7,241.20
    +16.00 (+0.22%)
     
  • AUD/USD

    0.7052
    -0.0042 (-0.59%)
     
  • OIL

    68.42
    +1.92 (+2.89%)
     
  • GOLD

    1,768.20
    +5.50 (+0.31%)
     
  • BTC-AUD

    80,423.21
    -461.98 (-0.57%)
     
  • CMC Crypto 200

    1,446.95
    +8.07 (+0.56%)
     
  • AUD/EUR

    0.6241
    -0.0033 (-0.53%)
     
  • AUD/NZD

    1.0406
    +0.0007 (+0.07%)
     
  • NZX 50

    12,676.50
    +6.26 (+0.05%)
     
  • NASDAQ

    15,990.76
    +113.04 (+0.71%)
     
  • FTSE

    7,141.95
    +12.74 (+0.18%)
     
  • Dow Jones

    34,639.79
    +617.75 (+1.82%)
     
  • DAX

    15,306.85
    +43.74 (+0.29%)
     
  • Hang Seng

    23,766.69
    -22.24 (-0.09%)
     
  • NIKKEI 225

    28,029.57
    +276.20 (+1.00%)
     

Cluster Headache Market to Surpass US$ 550.1 Million by 2028, Says Coherent Market Insights (CMI)

·4-min read

SEATTLE, Oct. 25, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global cluster headache market is estimated to be valued at US$ 355.2 Million in 2021 and is expected to exhibit a CAGR of 6.4% over the forecast period (2021-2028).

Key Trends and Analysis of the Global Cluster Headache Market:

The increasing approval of novel treatment options for cluster headache by regulatory authorities such as the U.S. Food and Drug Administration (FDA), is driving the growth of the global cluster headache market. For instance, according to the U.S. FDA News Release, released in June 2019, the U.S. FDA approved Emgality (galcanezumabgnlm) solution for injection for the treatment of episodic cluster headaches in adults. Emgality offers patients the first FDA-approved drug that reduces the frequency of episodic cluster headache attacks.

Furthermore, key players operating in the global cluster headache market are focusing on adoption of inorganic growth strategies such as agreements to increase their market presence in the global market. For instance, in June 2019, Dr. Reddy's Laboratories, an Indian multinational pharmaceutical company, signed an asset purchase agreement with Upsher-Smith, a U.S.-based generics company, to sell rights for its two neurology products, Zembrace and Tosymra. Zembrace and Tosymra are drugs used to treat migraine headaches and cluster headaches through different routes of delivery such as oral, topical, intravenous and others.

Request for Sample copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/4709

Key Market Takeaways:

The global cluster headache market is expected to exhibit a CAGR of 6.4% during the forecast period, owing to the increasing global geriatric population. According to World Population Prospects 2019 (United Nations, 2019), by 2050, one in six people will be over the age of 65 globally, which will be up from one in 11 people in 2019.

Among drug type, fast-acting drugs holds a dominant position in the global cluster headache market. Anti-inflammatory medications called corticosteroids, such as prednisone, are fast-acting preventive drugs that can be effective for several people with cluster headaches.

Among regions, North America dominates the global cluster headache market, due to advanced healthcare infrastructure along with the advent of advanced technologies to diagnose the syndrome and the increasing prevalence of migraines. Asia Pacific is expected to have the highest growth rate and the highest CAGR for the forecast period. This is due to increased spending on health infrastructure development, coupled with a growing geriatric population base.

Competitive Landscape:

Key players operating in the global cluster headache market include Zosano Pharma, Eli Lilly and Company, Lundbeck Seattle BioPharmaceutical, Winston Laboratories, GlaxoSmithKline plc., ElectroCore Medical LLC, Autonomic Technologies, Inc., AstraZeneca plc., Allergan plc., Bayer AG, F. Hoffmann-La Roche Ltd, Novartis AG, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Sanofi, and AbbVie Inc.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4709

Market Segmentation:

  • Global Cluster Headache Market, By Type:

    • Episodic

    • Chronic

  • Global Cluster Headache Market, By Drug Type:

    • Fast-acting Drugs

    • Long-term Drugs

    • Short-term Drugs

  • Global Cluster Headache Market, By Route of Administration:

    • Oral

    • Topical

    • Intravenous

    • Others

  • Global Cluster Headache Market, By Distribution Channel:

    • Hospital Pharmacies

    • Retail Pharmacies

    • Online Pharmacies

  • Global Cluster Headache Market, By Region:

    • North America

      • By Country

        • U.S.

        • Canada

    • Latin America

      • By Country

        • Brazil

        • Mexico

        • Argentina

        • Rest of Latin America

    • Europe

      • By Country

        • Germany

        • U.K.

        • France

        • Italy

        • Spain

        • Russia

        • Rest of Europe

    • Asia Pacific

      • By Country

        • China

        • India

        • Japan

        • Australia

        • South Korea

        • ASEAN

        • Rest of Asia Pacific

    • Middle East

      • By Country

        • GCC

        • Israel

        • Rest of Middle East

    • Africa

      • By Region/Country

        • South Africa

        • Central Africa

        • North Africa

Related Market Intelligence Reports:

Vagus Nerve Stimulators Market by Product Type (Implantable Devices, and External Devices), by Application (Epilepsy, Depression, Cluster Headache & Migraine, and Others), by Distribution Channel (Hospital, Specialty Pharmacy, and Others), by Distribution Channel (Hospital, Retail Pharmacy, and Online Pharmacy) and Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018-2026

Cold, Cough, and Sore Throat Remedies Market, By Drug Type (Antihistamines, Expectorants, Bronchodilators, Decongestants, Antibiotics, Others), By Formulation (Oral Syrups, Tablets/Pills, Nasal Drops, Lozenges, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores Supermarkets/Hypermarkets, E-Commerce/Online Pharmacies), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027


About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.

Follow Us: LinkedIn | Twitter

CONTACT: Mr. Shah Senior Client Partner – Business Development Coherent Market Insights Phone: US: +1-206-701-6702 UK: +44-020-8133-4027 Japan: +81-050-5539-1737 India: +91-848-285-0837 Email: sales@coherentmarketinsights.com Website: https://www.coherentmarketinsights.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting